



Clinical trial results:

A Randomized, Open Label, Phase 2 Study Of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who are Ineligible for Intensive Chemotherapy and/or Transplantation

Summary

EudraCT number	2014-000920-26
Trial protocol	DE ES NL GB DK BE HU IT
Global end of trial date	08 January 2018

Results information

Result version number	v1 (current)
This version publication date	25 September 2021
First version publication date	25 September 2021

Trial information

Trial identification

Sponsor protocol code	KCP-330-008
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02088541
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Karyopharm Therapeutics, Inc.
Sponsor organisation address	85 Wells Avenue, Newton, MA, United States, 02459
Public contact	Clinical Trial Information Desk, Karyopharm Therapeutics, Inc., clinicaltrials@karyopharm.com
Scientific contact	Clinical Trial Information Desk, Karyopharm Therapeutics, Inc., clinicaltrials@karyopharm.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 January 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	08 January 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main purpose of this study was to determine overall survival of selinexor as compared to physicians choice in subjects greater than or equal to (\geq) 60 years old with relapsed/refractory AML that requires treatment and were ineligible for intensive chemotherapy and/or transplantation.

Protection of trial subjects:

This study was monitored by Argint International KFT and BCN Clinical Research SL in Europe and Israel and the Sponsor in North America in accordance with Sponsor's procedures, which meet the ICH Harmonised Tripartite Guidelines for Good Clinical Practice (GCP), with applicable local regulations, and with the ethical principles outlined in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 May 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 18
Country: Number of subjects enrolled	Poland: 7
Country: Number of subjects enrolled	Spain: 42
Country: Number of subjects enrolled	United Kingdom: 13
Country: Number of subjects enrolled	Belgium: 16
Country: Number of subjects enrolled	Denmark: 5
Country: Number of subjects enrolled	France: 14
Country: Number of subjects enrolled	Germany: 44
Country: Number of subjects enrolled	Canada: 7
Country: Number of subjects enrolled	Israel: 5
Country: Number of subjects enrolled	Italy: 3
Country: Number of subjects enrolled	United States: 143
Worldwide total number of subjects	317
EEA total number of subjects	162

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	20
From 65 to 84 years	286
85 years and over	11

Subject disposition

Recruitment

Recruitment details:

A total of 317 subjects were enrolled at 95 sites between March 2014 (first subject enrolled) and 08 Jan 2018 (last subject completed study).

Pre-assignment

Screening details:

Subjects who met the eligibility criteria were randomized into 5 treatment groups: Selinexor Approximately 55mg/m² (60 to 120 mg based on body surface area); Selinexor 60 mg (PV<5)(Equivalent to 35 mg/m²); Selinexor 60 mg (PV ≥5)(Equivalent to 35 mg/m²); Physician's Choice 1 (PV<5) and Physician's Choice 2 (PV≥5).

Period 1

Period 1 title	Baseline (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Selinexor Approximately 55 mg/m ² (60 to 120 mg based on BSA)

Arm description:

Subjects under protocol versions (PV) less than (<) 5.0 (those who had one prior line of acute myeloid leukemia [AML] therapy), received oral selinexor tablets at a dose of approximately 55 mg/m² (milligrams per square meter) (60 to 120 mg based on BSA) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Arm type	Experimental
Investigational medicinal product name	Selinexor
Investigational medicinal product code	
Other name	KPT-330
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received Selinexor tablets, orally, at a dose of approximately 55 mg/m² (60 to 120 mg based on BSA) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Arm title	Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m ²)
------------------	--------------------------------------------------------------

Arm description:

Subjects under PV < 5.0 (those who had one prior line of AML therapy), receive oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m²), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Arm type	Experimental
Investigational medicinal product name	Selinexor
Investigational medicinal product code	
Other name	KPT-330
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received Selinexor tablets, orally, at a dose of 60 mg (equivalent to 35 mg/m²), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Arm title	Selinexor 60 mg (PV ≥5) (Equivalent to 35 mg/m ²)
------------------	---------------------------------------------------------------

Arm description:

Subjects under PV ≥ 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), receive oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m²) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Arm type	Experimental
Investigational medicinal product name	Selinexor
Investigational medicinal product code	
Other name	KPT-330
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received Selinexor tablets, orally, at a dose of 60 mg (equivalent to 35 mg/m²), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Arm title	Physician's Choice 1 (PV <5)
------------------	------------------------------

Arm description:

Subjects under PV < 5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.

Arm type	Active comparator
Investigational medicinal product name	Hydroxyurea
Investigational medicinal product code	
Other name	Hydroxycarbamide
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects under PV < 5.0 received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.

Arm title	Physician's Choice 2 (PV ≥ 5)
------------------	-------------------------------------

Arm description:

Subjects under PV ≥ 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.

Arm type	Active comparator
Investigational medicinal product name	Ara-C
Investigational medicinal product code	
Other name	Cytosine arabinoside
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.

Number of subjects in period 1	Selinexor Approximately 55 mg/m ² (60 to 120 mg based on BSA)	Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m ²)	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)
Started	71	27	118
Completed	0	0	0
Not completed	71	27	118
Consent withdrawn by subject	3	2	9
Physician decision	2	1	2

Disease progression	7	1	2
Study terminated by Sponsor	1	1	12
Adverse event, non-fatal	3	-	3
Death	51	21	85
Other	2	1	3
Subject treated with PC2 counted under this arm	-	-	1
Lost to follow-up	2	-	1

Number of subjects in period 1	Physician's Choice 1 (PV <5)	Physician's Choice 2 (PV ≥5)
Started	44	57
Completed	0	0
Not completed	44	57
Consent withdrawn by subject	7	10
Physician decision	-	2
Disease progression	3	1
Study terminated by Sponsor	2	6
Adverse event, non-fatal	3	-
Death	28	37
Other	1	1
Subject treated with PC2 counted under this arm	-	-
Lost to follow-up	-	-

Baseline characteristics

Reporting groups

Reporting group title	Selinexor Approximately 55 mg/m ² (60 to 120 mg based on BSA)
-----------------------	--------------------------------------------------------------------------

Reporting group description:

Subjects under protocol versions (PV) less than (<) 5.0 (those who had one prior line of acute myeloid leukemia [AML] therapy), received oral selinexor tablets at a dose of approximately 55 mg/m² (milligrams per square meter) (60 to 120 mg based on BSA) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Reporting group title	Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m ²)
-----------------------	--------------------------------------------------------------

Reporting group description:

Subjects under PV < 5.0 (those who had one prior line of AML therapy), receive oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m²), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Reporting group title	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)
-----------------------	----------------------------------------------------------------

Reporting group description:

Subjects under PV ≥ 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), receive oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m²) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Reporting group title	Physician's Choice 1 (PV <5)
-----------------------	------------------------------

Reporting group description:

Subjects under PV < 5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.

Reporting group title	Physician's Choice 2 (PV ≥ 5)
-----------------------	-------------------------------

Reporting group description:

Subjects under PV ≥ 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.

Reporting group values	Selinexor Approximately 55 mg/m ² (60 to 120 mg based on BSA)	Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m ²)	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)
Number of subjects	71	27	118
Age categorical Units: Subjects			
18-64 years	8	0	6
65-84 years	60	27	107
≥ 85 years	3	0	5
Gender categorical Units: Subjects			
Female	26	11	46
Male	45	16	72

Reporting group values	Physician's Choice 1 (PV <5)	Physician's Choice 2 (PV ≥ 5)	Total
Number of subjects	44	57	317
Age categorical Units: Subjects			
18-64 years	3	3	20
65-84 years	40	52	286
≥ 85 years	1	2	11

Gender categorical			
Units: Subjects			
Female	22	16	121
Male	22	41	196

End points

End points reporting groups

Reporting group title	Selinexor Approximately 55 mg/m ² (60 to 120 mg based on BSA)
-----------------------	--------------------------------------------------------------------------

Reporting group description:

Subjects under protocol versions (PV) less than (<) 5.0 (those who had one prior line of acute myeloid leukemia [AML] therapy), received oral selinexor tablets at a dose of approximately 55 mg/m² (milligrams per square meter) (60 to 120 mg based on BSA) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Reporting group title	Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m ²)
-----------------------	--------------------------------------------------------------

Reporting group description:

Subjects under PV < 5.0 (those who had one prior line of AML therapy), receive oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m²), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Reporting group title	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)
-----------------------	----------------------------------------------------------------

Reporting group description:

Subjects under PV ≥ 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), receive oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m²) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Reporting group title	Physician's Choice 1 (PV <5)
-----------------------	------------------------------

Reporting group description:

Subjects under PV < 5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.

Reporting group title	Physician's Choice 2 (PV ≥ 5)
-----------------------	-------------------------------

Reporting group description:

Subjects under PV ≥ 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.

Primary: Overall Survival

End point title	Overall Survival ^[1]
-----------------	---------------------------------

End point description:

Overall survival was defined as the time (in days) from the date of randomization to the date of death due to any cause. Subjects last known to be alive were censored at date of last contact. Intent-to-treat (ITT) population included all subjects who were randomized to study treatment under PV ≥ 5.0, regardless of whether or not they received study treatment. One subjects was randomized to receive selinexor 60 mg (PV ≥ 5) but was treated with physician's choice 2. Hence, this subjects was counted under selinexor 60 mg (PV ≥ 5).

End point type	Primary
----------------	---------

End point timeframe:

Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As pre-specified in the protocol, data was assessed and reported of the Selinexor 60 mg (PV ≥ 5) and Physician's Choice 2 (PV ≥ 5) arm only for this endpoint.

End point values	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)	Physician's Choice 2 (PV ≥ 5)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	57		
Units: Days				
median (confidence interval 95%)	94.0 (78.0 to 158.0)	170.0 (111.0 to 220.0)		

Statistical analyses

Statistical analysis title	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)
Comparison groups	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²) v Physician's Choice 2 (PV ≥ 5)
Number of subjects included in analysis	175
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4221
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	1.75

Primary: Percentage of Subjects With Overall Survival of at Least 3 Months (OS3.0)

End point title	Percentage of Subjects With Overall Survival of at Least 3 Months (OS3.0) ^[2]
-----------------	------------------------------------------------------------------------------------------

End point description:

Overall survival was defined as the time (in days) from the date of randomization to the date of death due to any cause. Subjects last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method. ITT population included all subjects who were randomized to study treatment under PV ≥ 5.0 , regardless of whether or not they received study treatment. One subjects was randomized to receive selinexor 60 mg (PV ≥ 5) but was treated with physician's choice 2. Hence, this subjects was counted under selinexor 60 mg (PV ≥ 5).

End point type	Primary
----------------	---------

End point timeframe:

From randomization (Day 1) up to 3 months

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As pre-specified in the protocol, data was assessed and reported of the Selinexor 60 mg (PV ≥ 5) and Physician's Choice 2 (PV ≥ 5) arm only for this endpoint.

End point values	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)	Physician's Choice 2 (PV ≥ 5)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	57		
Units: percent				
number (confidence interval 95%)	53.49 (43.54 to 62.44)	70.73 (55.60 to 81.52)		

Statistical analyses

Statistical analysis title	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)
Comparison groups	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²) v Physician's Choice 2 (PV ≥ 5)
Number of subjects included in analysis	175
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9464
Method	Logrank

Secondary: Percentage of Subjects With Complete Remission Rate (CRR) for Those Who Achieved Complete Remission (CR)

End point title	Percentage of Subjects With Complete Remission Rate (CRR) for Those Who Achieved Complete Remission (CR) ^[3]
-----------------	-------------------------------------------------------------------------------------------------------------------------

End point description:

CRR was analyzed using International Working Group (IWG) 2003 criteria, as the difference in the proportions of subjects with IWG results of CR. CR per IWG 2003 criteria was defined as morphologic presence of < 5 percentage (%) myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood absolute neutrophil count (ANC) > 1000 cells/microliter (mcL) and platelet count > 100,000/mcL, with no need for red blood cell (RBC) transfusions), and the absence of extramedullary disease. ITT population included all subjects who were randomized to study treatment under PV ≥ 5.0 , regardless of whether or not they received study treatment. One subjects was randomized to receive selinexor 60 mg (PV ≥ 5) but was treated with physician's choice 2. Hence, this subjects was counted under selinexor 60 mg (PV ≥ 5).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As pre-specified in the protocol, data was assessed and reported of the Selinexor 60 mg (PV ≥ 5) and Physician's Choice 2 (PV ≥ 5) arm only for this endpoint.

End point values	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)	Physician's Choice 2 (PV ≥ 5)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	57		
Units: percentage of subject				
number (confidence interval 95%)	5.1 (1.9 to	0.0 (0.0 to 6.3)		

Statistical analyses

Statistical analysis title	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)
Comparison groups	Physician's Choice 2 (PV ≥ 5) v Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)
Number of subjects included in analysis	175
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0986
Method	Cochran-Mantel-Haenszel

Secondary: Median Disease-Free Survival (DFS) for Subjects Who Achieved Complete Remission (CR)

End point title	Median Disease-Free Survival (DFS) for Subjects Who Achieved Complete Remission (CR) ^[4]
-----------------	-----------------------------------------------------------------------------------------------------

End point description:

DFS for CRR based on IWG criteria, was calculated from the first date of response of CR to the date of progression or recurrence, or date of death if progression or recurrence did not occur. Subjects who discontinued prior to disease progression or recurrence or did not progress as of the time of the analysis were censored at the time of last radiologic assessment. CR per IWG 2003 criteria was defined as morphologic presence of < 5 % myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC > 1000 cells/mcL and platelet count > 100,000/mcL, with no need for RBC transfusions), and the absence of extramedullary disease. ITT population. Here, "99999" indicates that upper limits of 95% CI was not estimable due to less number of subject. This endpoint was only defined for CR subjects. For Physician Choice 2, there was zero CR subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As pre-specified in the protocol, data was assessed and reported of the Selinexor 60 mg (PV ≥ 5) and Physician's Choice 2 (PV ≥ 5) arm only for this endpoint.

End point values	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)	Physician's Choice 2 (PV ≥ 5)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	0 ^[5]		
Units: Days				
median (confidence interval 95%)	121 (49.0 to 99999)	(to)		

Notes:

[5] - No subjects in this group achieved CR.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Modified Complete Remission Rate (mCRR) for Those Who Achieved Complete Remission (CR) or Complete Remission With Incomplete Hematologic Recovery (Cri)

End point title	Percentage of Subjects With Modified Complete Remission Rate (mCRR) for Those Who Achieved Complete Remission (CR) or Complete Remission With Incomplete Hematologic Recovery (Cri) ^[6]
-----------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

mCRR was defined as the point estimate of the percentage of subjects who had CR, CRi, or CRp. Responses defined as per IWG 2003 response criteria: Morphologic CR: < 5% myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC > 1000 cells/mcL and platelet count > 100,000/mcL, with no need for RBC transfusions), and the absence of extramedullary disease. Morphologic CRp: All criteria for CR except for residual neutropenia (<1x10⁹/L) or thrombocytopenia (<100 x10⁹/L), Cri (< 5% bone marrow blasts with residual neutropenia [ANC < 1000 cells/mcL] or thrombocytopenia [platelets < 100,000/mcL]), normal maturation of all cellular components in the bone marrow, no extramedullary disease and transfusion independent. ITT population included all subjects who were randomized to study treatment under PV>=5.0, regardless of whether or not they received study treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As pre-specified in the protocol, data was assessed and reported of the Selinexor 60 mg (PV >=5) and Physician's Choice 2 (PV >=5) arm only for this endpoint.

End point values	Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m ²)	Physician's Choice 2 (PV >=5)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	57		
Units: percentage of subjects				
number (confidence interval 95%)	11.9 (6.6 to 19.1)	3.5 (0.4 to 12.1)		

Statistical analyses

Statistical analysis title	Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m ²)
Comparison groups	Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m ²) v Physician's Choice 2 (PV >=5)
Number of subjects included in analysis	175
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0844
Method	Cochran-Mantel-Haenszel

Secondary: Median Disease-Free Survival (DFS) for Subjects Who Achieved Complete Remission or CR With Incomplete Hematologic Recovery (CRi) or Complete Remission With Incomplete Platelet Recovery (CRp)

End point title	Median Disease-Free Survival (DFS) for Subjects Who Achieved Complete Remission or CR With Incomplete Hematologic Recovery (CRi) or Complete Remission With Incomplete Platelet Recovery (CRp) ^[7]
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

DFS: the duration from start of the complete response achieved until disease progression or death from any cause. Responses defined by IWG 2003 Response Criteria: morphologic CR: <5% myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC > 1000 cells/mcL and PC > 100,000/mcL, with no need for RBC transfusions), and the absence of extramedullary disease. Morphologic CRp: All criteria for CR except for residual neutropenia < $1 \times 10^9/L$ or thrombocytopenia (< $100 \times 10^9/L$), Cri < 5% bone marrow blasts with residual neutropenia [ANC < 1000 cells/mcL] or thrombocytopenia [platelets < 100,000/mcL], normal maturation of all cellular components in the bone marrow, no extramedullary disease and transfusion independent. ITT Population. Number of subjects analysed signifies those subjects evaluable for this endpoint. Here, "99 and 99999" indicates that upper and lower limits of 95% CI was not estimable due to less number of subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As pre-specified in the protocol, data was assessed and reported of the Selinexor 60 mg (PV ≥ 5) and Physician's Choice 2 (PV ≥ 5) arm only for this endpoint.

End point values	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)	Physician's Choice 2 (PV ≥ 5)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	2		
Units: Days				
median (confidence interval 95%)	175.0 (61.0 to 288.0)	106.0 (99 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Overall Response Rate (ORR)

End point title	Percentage of Subjects With Overall Response Rate (ORR) ^[8]
-----------------	------------------------------------------------------------------------

End point description:

Overall response rate was defined as the point estimate of the percentage of subjects who achieved CR (disappearance of all target and non-target lesions), partial response (PR) (≥ 30 % decrease in sum of longest diameters of target lesions taking as reference baseline sum longest diameters associated to non-progressive disease response for non-target lesions). CRi; < 5% BM blasts with residual neutropenia [ANC < 1000 cells/mcL] or thrombocytopenia [platelets < 100,000/mcL]. CRp; All criteria for CR except for residual neutropenia (< $1 \times 10^9/L$) or thrombocytopenia (< $100 \times 10^9/L$) and morphologic leukemia-free state (MLFS); morphologic BM blast clearance to < 5% in a marrow sample in which ≤ 200 cells enumerated or cellularity is ≥ 10%, in absence of blasts with Auer rods, no hematologic recovery required. ITT population included all subjects who were randomized to study treatment under PV ≥ 5.0, regardless of whether or not they received study treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As pre-specified in the protocol, data was assessed and reported of the Selinexor 60 mg (PV ≥ 5) and Physician's Choice 2 (PV ≥ 5) arm only for this endpoint.

End point values	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)	Physician's Choice 2 (PV ≥ 5)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	57		
Units: percentage of subjects				
number (confidence interval 95%)	13.6 (8.0 to 21.1)	8.8 (2.9 to 19.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR)

End point title	Duration of Response (DOR) ^[9]
-----------------	-------------------------------------------

End point description:

DOR was calculated from date of response of CR, CRi, CRp, MLFS, or PR to date of progression or recurrence based on IWG criteria. CR: $<5\%$ myeloblasts in bone marrow, absence of circulating blasts, hematologic recovery (peripheral blood ANC >1000 cells/mcL, platelet count $>100,000$ /mcL, no need for RBC transfusions), absence of extramedullary disease. PR: No circulating blasts, neutrophil count $\geq 1.0 \times 10^9/L$, platelet count $\geq 100 \times 10^9/L$, $\geq 50\%$ reduction in bone marrow blast to 6% to 25%, or blasts less than or equal to (\leq) 5% if Auer rods are present. Number of subjects analysed signifies those subjects evaluable for this endpoint. Here, "99999" indicates that upper and lower limits of 95% CI was not estimable due to less number of subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As pre-specified in the protocol, data was assessed and reported of the Selinexor 60 mg (PV ≥ 5) and Physician's Choice 2 (PV ≥ 5) arm only for this endpoint.

End point values	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)	Physician's Choice 2 (PV ≥ 5)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	16	5		
Units: Days				
median (confidence interval 95%)	204.0 (117.0 to 334.0)	148.0 (85.0 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Disease Control Rate (DCR)

End point title	Percentage of Subjects With Disease Control Rate (DCR) ^[10]
-----------------	------------------------------------------------------------------------

End point description:

DCR: Point estimate of % of subjects with CR, CRi, CRp, MLFS, PR, or SD for ≤ 4 weeks. CR: $< 5\%$ myeloblasts in bone marrow (BM), absence of circulating blasts, hematologic recovery (peripheral blood ANC > 1000 cells/mcL and platelet count $> 100,000$ /mcL, no need of RBC transfusions), absence of extramedullary disease. PR: No circulating blasts, Neutrophil count $\geq 1.0 \times 10^9$ /L, Platelet count $\geq 100 \times 10^9$ /L, $\geq 50\%$ reduction in BM blast to 6% to 25% , or blasts $\leq 5\%$ if Auer rods are present. CRp: All criteria for CR except for residual neutropenia ($< 1 \times 10^9$ /L) or thrombocytopenia ($< 100 \times 10^9$ /L), CRi: $< 5\%$ BM blasts with residual neutropenia [ANC < 1000 cells/mcL] or thrombocytopenia [platelets $< 100,000$ /mcL]. MLFS: morphologic BM blast clearance to $< 5\%$ in a marrow sample in which ≤ 200 cells enumerated or cellularity is $\geq 10\%$, in absence of blasts with Auer rods, no hematologic recovery required, SD: failure to achieve a response but not meeting criteria for disease progression over period of > 4 weeks.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 4 weeks from the date of randomization to the date of progression or recurrence based on IWG criteria

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As pre-specified in the protocol, data was assessed and reported of the Selinexor 60 mg (PV ≥ 5) and Physician's Choice 2 (PV ≥ 5) arm only for this endpoint.

End point values	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)	Physician's Choice 2 (PV ≥ 5)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	57		
Units: percentage of subjects				
number (confidence interval 95%)	50.8 (41.5 to 60.2)	40.4 (27.6 to 54.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Disease Control Rate

End point title	Duration of Disease Control Rate ^[11]
-----------------	--------------------------------------------------

End point description:

Duration of DCR calculated for all subjects with DCR. CR: $< 5\%$ myeloblasts in BM, absence of circulating blasts, hematologic recovery (peripheral blood ANC > 1000 cells/mcL and platelet count $>$

100,000/mcL, no need for RBC transfusions), absence of extra medullary disease. PR: No circulating blasts, Neutrophil count $\geq 1.0 \times 10^9/L$, Platelet count $\geq 100 \times 10^9/L$, $\geq 50\%$ reduction in BM blast to 6% to 25%, or blasts $\leq 5\%$ if Auer rods are present. CRp: All criteria for CR except for residual neutropenia ($< 1 \times 10^9/L$), CRi; $< 5\%$ BM blasts with residual neutropenia [ANC < 1000 cells/mcL]. MLFS; morphologic BM blast clearance to $< 5\%$ in a marrow sample in which ≤ 200 cells enumerated/cellularity is $\geq 10\%$, in absence of blasts with Auer rods, no hematologic recovery required and SD; failure to achieve a response but not meeting criteria for disease progression over period of > 4 weeks. Here, "number of subjects analysed" signifies those subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 4 weeks from the date of randomization to the date of progression or recurrence based on IWG criteria

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As pre-specified in the protocol, data was assessed and reported of the Selinexor 60 mg (PV ≥ 5) and Physician's Choice 2 (PV ≥ 5) arm only for this endpoint.

End point values	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)	Physician's Choice 2 (PV ≥ 5)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	60	23		
Units: Days				
median (confidence interval 95%)	187 (125 to 261)	233 (155 to 263)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Quality of Life (QoL) and Patient-Reported Outcomes (Functional Assessment of Cancer Therapy -Leukemia [FACT-Leu])

End point title	Change From Baseline in Quality of Life (QoL) and Patient-Reported Outcomes (Functional Assessment of Cancer Therapy -Leukemia [FACT-Leu]) ^[12]
-----------------	------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

QoL was assessed by FACT-Leu. FACT-Leu combines General version of the FACT-G with a leukemia-specific sub-scale (17 items). Sub-scales for the FACT-G are Physical Well-Being (7 items), Social/Family Well-Being (7 items), Emotional Well-Being (6 items) & Functional Well-Being (7 items). TOI (total of 31 items) was primary measurement of interest, comprising Physical and Functional sub-scales plus the leukemia - specific sub-scale. Each item was rated on a 5-point Likert scale. Range from 0=(Not at all) to 4=(Very much); TOI had a score ranging from 0-124. Higher scores indicated improvement in well being. QoL was performed at baseline (prior to first dose of study treatment), Day 1 of each cycle on or after second, and at final visit. Here, "number of subjects analysed" signifies those subjects evaluable for this endpoint and "number analysed" signifies those subjects evaluable for specified categories. Here, "99999" indicates SD was not estimated due to single and no subject.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Day 1 of each treatment cycle (a maximum of 20 cycles: 28 days per cycle) up to 30 days after last dose of study drug (final visit)

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Per protocol, only descriptive analyses was planned for this endpoint.

End point values	Selinexor 60 mg (PV ≥ 5) (Equivalent to 35 mg/m ²)	Physician's Choice 2 (PV ≥ 5)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	71	34		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Baseline (n=65, 29)	70.5 (\pm 15.20)	75.4 (\pm 14.74)		
C2D1 (n=59, 25)	0.5 (\pm 16.50)	-1.9 (\pm 15.18)		
C3D1 (n=39, 16)	-1.9 (\pm 16.88)	-5.4 (\pm 22.25)		
C4D1 (n=26, 7)	-1.2 (\pm 15.70)	-7.4 (\pm 25.41)		
C5D1 (n=20, 7)	-2.4 (\pm 16.84)	1.9 (\pm 8.40)		
C6D1 (n=19, 6)	-3.4 (\pm 15.66)	-4.7 (\pm 13.20)		
C7D1 (n=15, 5)	-5.0 (\pm 17.21)	-11.8 (\pm 27.43)		
C8D1 (n=15, 5)	-3.9 (\pm 15.78)	-10.6 (\pm 7.83)		
C9D1 (n=11, 4)	-2.7 (\pm 7.47)	-8.0 (\pm 8.49)		
C10D1 (n=9, 3)	2.4 (\pm 13.19)	-10.7 (\pm 12.70)		
C11D1 (n=7, 2)	-0.1 (\pm 8.65)	-10.0 (\pm 9.90)		
C12D1 (n=6, 2)	-3.7 (\pm 11.69)	-7.0 (\pm 16.97)		
C13D1 (n=4, 1)	-3.3 (\pm 6.40)	-9.0 (\pm 99999)		
C14D1 (n=3, 1)	-4.0 (\pm 3.46)	-15.0 (\pm 99999)		
C15D1 (n=2, 1)	1.5 (\pm 3.54)	-10.0 (\pm 99999)		
C16D1 (n=0, 1)	99999 (\pm 99999)	-15.0 (\pm 99999)		
C17D1 (n=1, 1)	-15.0 (\pm 99999)	-7.0 (\pm 99999)		
C18D1 (n=1, 0)	-1.0 (\pm 99999)	99999 (\pm 99999)		
C19D1 (n=1, 0)	-12.0 (\pm 99999)	99999 (\pm 99999)		
C20D1 (n=1, 0)	-14.0 (\pm 99999)	99999 (\pm 99999)		
Final visit (n=25, 12)	2.5 (\pm 17.71)	-1.7 (\pm 20.46)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Health Questionnaire Visual Analogue Scale (VAS)

End point title	Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Health Questionnaire Visual Analogue Scale (VAS) ^[13]
-----------------	---------------------------------------------------------------------------------------------------------------------------------------

End point description:

EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight

problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ VAS. EQ-5D-5-VAS records subject's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable), higher scores indicating a better health state. PP Population. Here, "number of subjects analysed" signifies those subjects evaluable for this endpoint and "number analysed" signifies those subjects evaluable for specified categories. Here, "99999" indicates standard deviation was not estimated due to single and no subject at that time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Day 1 of each treatment cycle (a maximum of 20 cycles: 28 days per cycle) up to 30 days after last dose of study drug (final visit)

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As pre-specified in the protocol, data was assessed and reported of the Selinexor 60 mg (PV >=5) and Physician's Choice 2 (PV >=5) arm only for this endpoint.

End point values	Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m ²)	Physician's Choice 2 (PV >=5)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	71	34		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Baseline (n=59, 30)	67.9 (± 19.51)	63.5 (± 21.10)		
C2D1 (n=51, 25)	-7.5 (± 23.45)	0.8 (± 15.82)		
C3D1 (n=35, 17)	-13.3 (± 25.04)	-5.2 (± 23.54)		
C4D1 (n=23, 9)	-6.1 (± 20.80)	-5.0 (± 11.46)		
C5D1 (n=18, 10)	-0.9 (± 20.83)	-2.0 (± 15.31)		
C6D1 (n=17, 7)	-11.2 (± 25.90)	-1.4 (± 24.10)		
C7D1 (n=14, 5)	-3.7 (± 23.91)	4.0 (± 10.84)		
C8D1 (n=13, 5)	0.1 (± 16.77)	5.0 (± 9.35)		
C9D1 (n=9, 4)	4.6 (± 13.25)	5.0 (± 10.80)		
C10D1 (n=7, 4)	0.7 (± 18.58)	6.3 (± 15.48)		
C11D1 (n=6, 2)	0.8 (± 18.55)	-5.0 (± 21.21)		
C12D1 (n=6, 2)	3.3 (± 16.63)	-5.0 (± 28.28)		
C13D1 (n=3, 1)	6.7 (± 20.21)	10.0 (± 99999)		
C14D1 (n=3, 1)	6.7 (± 25.66)	15.0 (± 99999)		
C15D1 (n=2, 1)	3.5 (± 30.41)	-10.0 (± 99999)		
C16D1 (n=0, 1)	99999 (± 99999)	20 (± 99999)		
C17D1 (n=1, 1)	25.0 (± 99999)	-5.0 (± 99999)		
C18D1 (n=1, 0)	25.0 (± 99999)	99999 (± 99999)		
C19D1 (n=1, 0)	30.0 (± 99999)	99999 (± 99999)		
C20D1 (n=1, 0)	35.0 (± 99999)	99999 (± 99999)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From start of study drug administration to 30 days after last dose of study drug (approximately 48 months)

Adverse event reporting additional description:

Same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another subjects, or one subject may have experienced both a serious and non-serious event during the study.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

Reporting groups

Reporting group title	Selinexor Approximately 55 mg/m ² (60 to 120 mg Based on BSA)
-----------------------	--------------------------------------------------------------------------

Reporting group description:

Subjects under PV <5.0 (those who had one prior line of AML therapy), received oral selinexor tablets at a dose of approximately 55 mg/m² (60 to 120 mg based on BSA) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Reporting group title	Selinexor 60mg (PV<5) (Equivalent to 35 mg/m ²)
-----------------------	-------------------------------------------------------------

Reporting group description:

Subjects under PV <5.0 (those who had one prior line of AML therapy), received oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m²), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Reporting group title	Selinexor 60mg (PV ≥5) (Equivalent to 35 mg/m ²)
-----------------------	--------------------------------------------------------------

Reporting group description:

Subjects under PV ≥5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m²) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).

Reporting group title	Physician's Choice 1 (PV <5)
-----------------------	------------------------------

Reporting group description:

Subjects under PV <5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.

Reporting group title	Physician's Choice 2 (PV ≥5)
-----------------------	------------------------------

Reporting group description:

Subjects under PV ≥5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.

Serious adverse events	Selinexor Approximately 55 mg/m ² (60 to 120 mg Based on BSA)	Selinexor 60mg (PV<5) (Equivalent to 35 mg/m ²)	Selinexor 60mg (PV ≥5) (Equivalent to 35 mg/m ²)
Total subjects affected by serious adverse events			
subjects affected / exposed	58 / 71 (81.69%)	15 / 27 (55.56%)	89 / 115 (77.39%)
number of deaths (all causes)	51	21	85
number of deaths resulting from adverse events	24	3	28

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cerebellar tumour			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	4 / 115 (3.48%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic aneurysm			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
General physical health deterioration			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 2
Fatigue			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	8 / 115 (6.96%)
occurrences causally related to treatment / all	1 / 1	0 / 0	7 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	2 / 2
Pyrexia			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 71 (5.63%)	1 / 27 (3.70%)	7 / 115 (6.09%)
occurrences causally related to treatment / all	2 / 4	0 / 1	1 / 7
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Condition aggravated			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Asthenia alternative assessment type: Systematic			
subjects affected / exposed	3 / 71 (4.23%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	3 / 3	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances Social stay hospitalisation alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders Vaginal haemorrhage alternative assessment type: Systematic			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Respiratory failure			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 2	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Acute respiratory failure			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Haemoptysis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Pneumonia aspiration			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Dyspnoea			
alternative assessment type: Systematic			

subjects affected / exposed	2 / 71 (2.82%)	1 / 27 (3.70%)	3 / 115 (2.61%)
occurrences causally related to treatment / all	0 / 2	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cough			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary mass			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 71 (5.63%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	3 / 4	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organic brain syndrome			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Weight decreased			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
C-reactive protein increased			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram change			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcus test positive			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin T increased			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vitamin B12 decreased			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Subdural haematoma			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Subdural haemorrhage			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Subarachnoid haemorrhage alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation alternative assessment type: Systematic			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 3
Cardiac failure alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac failure congestive alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardio-respiratory arrest alternative assessment type: Systematic			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Acute coronary syndrome			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus bradycardia			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachyarrhythmia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral haemorrhage			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cerebrovascular accident alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Dizziness alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	1 / 1	0 / 0	2 / 2
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Embolic stroke alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Haemorrhage intracranial alternative assessment type: Systematic			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Haemorrhagic cerebral infarction alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Loss of consciousness alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1

Syncope				
alternative assessment type: Systematic				
subjects affected / exposed	2 / 71 (2.82%)	1 / 27 (3.70%)	3 / 115 (2.61%)	
occurrences causally related to treatment / all	1 / 2	1 / 1	1 / 3	
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0	
Ataxia				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Cerebral infarction				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Encephalopathy				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Headache				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Ischaemic stroke				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Presyncope				
alternative assessment type: Systematic				

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Febrile neutropenia			
alternative assessment type: Systematic			
subjects affected / exposed	16 / 71 (22.54%)	4 / 27 (14.81%)	20 / 115 (17.39%)
occurrences causally related to treatment / all	8 / 16	4 / 4	11 / 20
deaths causally related to treatment / all	1 / 2	1 / 1	2 / 4
Anaemia			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	1 / 2	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	1 / 1	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukostasis syndrome			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic infarction			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 71 (4.23%)	1 / 27 (3.70%)	6 / 115 (5.22%)
occurrences causally related to treatment / all	3 / 3	1 / 1	4 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Vomiting			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 71 (5.63%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences causally related to treatment / all	3 / 4	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticular perforation			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal haemorrhage			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mouth ulceration			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth loss			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hepatobiliary disorders			
Cholecystitis acute			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Oliguria			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Renal failure			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Bone pain			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			

alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
alternative assessment type: Systematic			
subjects affected / exposed	10 / 71 (14.08%)	4 / 27 (14.81%)	10 / 115 (8.70%)
occurrences causally related to treatment / all	3 / 10	3 / 4	3 / 10
deaths causally related to treatment / all	2 / 5	1 / 1	1 / 5
Lung infection			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 71 (4.23%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 3	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 0
Sepsis			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 71 (11.27%)	1 / 27 (3.70%)	3 / 115 (2.61%)
occurrences causally related to treatment / all	4 / 8	0 / 1	1 / 3
deaths causally related to treatment / all	1 / 3	0 / 0	0 / 1
Septic shock			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	2 / 3
Escherichia sepsis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Pneumonia fungal			
alternative assessment type: Systematic			

subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Klebsiella sepsis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Sinusitis			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Urinary tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Urosepsis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infection				
alternative assessment type:				
Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Lower respiratory tract infection				
alternative assessment type:				
Systematic				
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Aspergillus infection				
alternative assessment type:				
Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Biliary sepsis				
alternative assessment type:				
Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Biliary tract infection				
alternative assessment type:				
Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Clostridium difficile infection				
alternative assessment type:				
Systematic				
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Diverticulitis				
alternative assessment type:				
Systematic				

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fungal infection			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrotising fasciitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic sepsis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Penile infection			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis bacterial			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Perirectal abscess				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Pneumocystis jirovecii pneumonia				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Sialoadenitis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Skin infection				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Soft tissue infection				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Tonsillitis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Upper respiratory tract infection				
alternative assessment type: Systematic				

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal abscess			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vulval cellulitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
alternative assessment type: Systematic			
subjects affected / exposed	5 / 71 (7.04%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	5 / 5	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	6 / 115 (5.22%)
occurrences causally related to treatment / all	1 / 1	0 / 0	6 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
alternative assessment type: Systematic			
subjects affected / exposed	5 / 71 (7.04%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	2 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
alternative assessment type: Systematic			

subjects affected / exposed	3 / 71 (4.23%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	3 / 3	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fluid overload			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercreatininaemia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophagia			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Physician's Choice 1 (PV <5)	Physician's Choice 2 (PV >=5)	
Total subjects affected by serious adverse events			
subjects affected / exposed	25 / 39 (64.10%)	30 / 45 (66.67%)	
number of deaths (all causes)	28	38	
number of deaths resulting from	7	9	

adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cerebellar tumour			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Basal cell carcinoma			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypotension			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
General physical health deterioration			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 39 (5.13%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Condition aggravated			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Multiple organ dysfunction syndrome alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia alternative assessment type: Systematic			
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise alternative assessment type: Systematic			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances Social stay hospitalisation alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders Vaginal haemorrhage alternative assessment type: Systematic			

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Respiratory failure			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pleural effusion			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	2 / 45 (4.44%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cough			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary mass			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Confusional state			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucination			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Organic brain syndrome			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Weight decreased			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood alkaline phosphatase increased			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
C-reactive protein increased			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram change			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcus test positive			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin T increased			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitamin B12 decreased			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Fall			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Atrial fibrillation			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac failure			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ventricular fibrillation			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute coronary syndrome			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus bradycardia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachyarrhythmia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebral haemorrhage			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)		
occurrences causally related to treatment / all	0 / 0	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 1		
Cerebrovascular accident				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Dizziness				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Embolic stroke				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Haemorrhage intracranial				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Haemorrhagic cerebral infarction				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Loss of consciousness				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		

Syncope				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Ataxia				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Cerebral infarction				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Encephalopathy				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Headache				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Ischaemic stroke				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Presyncope				
alternative assessment type: Systematic				

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Febrile neutropenia			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 39 (20.51%)	16 / 45 (35.56%)	
occurrences causally related to treatment / all	5 / 8	9 / 16	
deaths causally related to treatment / all	0 / 0	2 / 2	
Anaemia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	3 / 45 (6.67%)	
occurrences causally related to treatment / all	0 / 0	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukostasis syndrome			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic infarction			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Cataract			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Diarrhoea			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Constipation				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Diverticular perforation				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Large intestinal haemorrhage				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Mouth ulceration				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Nausea				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Tooth loss				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		

Hepatobiliary disorders			
Cholecystitis acute			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperbilirubinaemia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oliguria			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Bone pain			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			

alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumonia			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 39 (10.26%)	3 / 45 (6.67%)	
occurrences causally related to treatment / all	2 / 4	1 / 3	
deaths causally related to treatment / all	0 / 1	1 / 1	
Lung infection			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 39 (7.69%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Sepsis			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 39 (7.69%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Septic shock			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Escherichia sepsis			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
Pneumonia fungal			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)		
occurrences causally related to treatment / all	0 / 0	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 1		
Klebsiella sepsis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Sinusitis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Urinary tract infection				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	1 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Urosepsis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)		
occurrences causally related to treatment / all	0 / 0	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 1		
Cellulitis				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)		
occurrences causally related to treatment / all	0 / 1	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 0		
Device related infection				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)		
occurrences causally related to treatment / all	1 / 1	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 0		

Infection				
alternative assessment type:				
Systematic				
subjects affected / exposed	0 / 39 (0.00%)	2 / 45 (4.44%)		
occurrences causally related to treatment / all	0 / 0	1 / 2		
deaths causally related to treatment / all	0 / 0	0 / 0		
Lower respiratory tract infection				
alternative assessment type:				
Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Aspergillus infection				
alternative assessment type:				
Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Biliary sepsis				
alternative assessment type:				
Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Biliary tract infection				
alternative assessment type:				
Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Clostridium difficile infection				
alternative assessment type:				
Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Diverticulitis				
alternative assessment type:				
Systematic				

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Fungal infection				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Laryngitis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Necrotising fasciitis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Neutropenic sepsis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Penile infection				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Arthritis bacterial				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		

Perirectal abscess				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Pneumocystis jirovecii pneumonia				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Sialoadenitis				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Skin infection				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Soft tissue infection				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	0 / 0	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Tonsillitis				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)		
occurrences causally related to treatment / all	1 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
Upper respiratory tract infection				
alternative assessment type: Systematic				

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal abscess			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval cellulitis			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid overload			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercreatininaemia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Failure to thrive			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypophagia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Selinexor Approximately 55 mg/m ² (60 to 120 mg Based on BSA)	Selinexor 60mg (PV<5) (Equivalent to 35 mg/m ²)	Selinexor 60mg (PV ≥5) (Equivalent to 35 mg/m ²)
Total subjects affected by non-serious adverse events subjects affected / exposed	71 / 71 (100.00%)	27 / 27 (100.00%)	113 / 115 (98.26%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute Myeloid Leukaemia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Basal Cell Carcinoma			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Chloroma			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Leukaemic Infiltration			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Uterine Leiomyoma			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Vascular disorders			
Hypotension			
subjects affected / exposed	6 / 71 (8.45%)	1 / 27 (3.70%)	11 / 115 (9.57%)
occurrences (all)	6	1	11
Haematoma			
subjects affected / exposed	0 / 71 (0.00%)	2 / 27 (7.41%)	5 / 115 (4.35%)
occurrences (all)	0	2	5
Hypertension			
subjects affected / exposed	4 / 71 (5.63%)	2 / 27 (7.41%)	2 / 115 (1.74%)
occurrences (all)	4	2	2
Pallor			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	1	0	3
Haemorrhage			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2

Phlebitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Thrombophlebitis			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Orthostatic Hypotension			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	2	0	1
Deep Vein Thrombosis			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Flushing			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Circulatory Collapse			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Embolism			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Hot Flush			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Intermittent Claudication			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Lymphoedema			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Poor Peripheral Circulation			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Thrombophlebitis Superficial			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0

Venous Thrombosis subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
General disorders and administration site conditions			
Fatigue subjects affected / exposed occurrences (all)	33 / 71 (46.48%) 33	13 / 27 (48.15%) 13	50 / 115 (43.48%) 50
Pyrexia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	8 / 71 (11.27%) 8	5 / 27 (18.52%) 5	28 / 115 (24.35%) 28
Oedema peripheral alternative assessment type: Systematic subjects affected / exposed occurrences (all)	17 / 71 (23.94%) 17	5 / 27 (18.52%) 5	21 / 115 (18.26%) 21
Asthenia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	17 / 71 (23.94%) 17	6 / 27 (22.22%) 6	22 / 115 (19.13%) 22
Malaise subjects affected / exposed occurrences (all)	2 / 71 (2.82%) 2	1 / 27 (3.70%) 1	8 / 115 (6.96%) 8
Oedema subjects affected / exposed occurrences (all)	2 / 71 (2.82%) 2	0 / 27 (0.00%) 0	5 / 115 (4.35%) 5
Chills subjects affected / exposed occurrences (all)	1 / 71 (1.41%) 1	1 / 27 (3.70%) 1	5 / 115 (4.35%) 5
Mucosal Inflammation subjects affected / exposed occurrences (all)	3 / 71 (4.23%) 3	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Pain subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	7 / 115 (6.09%) 7
Gait Disturbance			

subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	2	0	2
General Physical Health Deterioration			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Injection Site Bruising			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Non-Cardiac Chest Pain			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Ulcer			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	2	0	1
Catheter Site Haemorrhage			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Face Oedema			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Generalised Oedema			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Secretion Discharge			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Catheter Site Haematoma			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Chest Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Drug Intolerance			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Extravasation			

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Feeling Cold			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Granuloma			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Hernia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Impaired Healing			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Infusion Site Haemorrhage			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Injection Site Discolouration			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Injection Site Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Mucosal Dryness			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Nodule			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Peripheral Swelling			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Swelling			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Decreased appetite			

subjects affected / exposed occurrences (all)	41 / 71 (57.75%) 41	12 / 27 (44.44%) 12	61 / 115 (53.04%) 61
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Reproductive system and breast disorders Breast Pain subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	0 / 115 (0.00%) 0
Breast Swelling subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Gynaecomastia subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	0 / 115 (0.00%) 0
Nipple Pain subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Oedema Genital subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Ovarian Cyst subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Testicular Oedema subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	0 / 115 (0.00%) 0
Vaginal Haemorrhage subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	14 / 71 (19.72%) 14	5 / 27 (18.52%) 5	24 / 115 (20.87%) 24
Epistaxis			

subjects affected / exposed	13 / 71 (18.31%)	3 / 27 (11.11%)	25 / 115 (21.74%)
occurrences (all)	13	3	25
Cough			
subjects affected / exposed	12 / 71 (16.90%)	3 / 27 (11.11%)	15 / 115 (13.04%)
occurrences (all)	12	3	15
Oropharyngeal Pain			
subjects affected / exposed	3 / 71 (4.23%)	2 / 27 (7.41%)	3 / 115 (2.61%)
occurrences (all)	3	2	3
Productive Cough			
subjects affected / exposed	4 / 71 (5.63%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	4	0	3
Haemoptysis			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	2	0	2
Dyspnoea Exertional			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	4 / 115 (3.48%)
occurrences (all)	1	0	4
Nasal Congestion			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	4 / 115 (3.48%)
occurrences (all)	1	1	4
Pleural Effusion			
subjects affected / exposed	1 / 71 (1.41%)	2 / 27 (7.41%)	2 / 115 (1.74%)
occurrences (all)	1	2	2
Hypoxia			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	2	0	1
Rhinorrhoea			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Wheezing			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Atelectasis			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Hiccups			

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Pleuritic Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Respiratory Failure			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Pulmonary Oedema			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Sinus Congestion			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Sinus Pain			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Upper-Airway Cough Syndrome			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Chronic Obstructive Pulmonary Disease			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Dysphonia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Laryngeal Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Lung Consolidation			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Lung Infiltration			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0

Nasal Dryness			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Nasal Inflammation			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Paranasal Sinus Discomfort			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Pharyngeal Inflammation			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Pneumonitis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Pulmonary Mass			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Rales			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Respiratory Tract Congestion			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Rhinitis Allergic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Rhonchi			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Sinus Disorder			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Tachypnoea			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1

Tonsillar Erythema subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	0 / 115 (0.00%) 0
Tonsillar Hypertrophy subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	0 / 115 (0.00%) 0
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	10 / 71 (14.08%) 10	4 / 27 (14.81%) 4	7 / 115 (6.09%) 7
Confusional State subjects affected / exposed occurrences (all)	5 / 71 (7.04%) 5	2 / 27 (7.41%) 2	8 / 115 (6.96%) 8
Anxiety subjects affected / exposed occurrences (all)	2 / 71 (2.82%) 2	2 / 27 (7.41%) 2	4 / 115 (3.48%) 4
Depression subjects affected / exposed occurrences (all)	2 / 71 (2.82%) 2	2 / 27 (7.41%) 2	2 / 115 (1.74%) 2
Agitation subjects affected / exposed occurrences (all)	6 / 71 (8.45%) 6	0 / 27 (0.00%) 0	0 / 115 (0.00%) 0
Restlessness subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	2 / 27 (7.41%) 2	0 / 115 (0.00%) 0
Abnormal Dreams subjects affected / exposed occurrences (all)	1 / 71 (1.41%) 1	0 / 27 (0.00%) 0	0 / 115 (0.00%) 0
Bulimia Nervosa subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Delirium subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Disorientation			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Flat Affect			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Hallucination, Visual			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Irritability			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Listless			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Mental Disorder			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Mental Status Changes			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Nervousness			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Psychomotor Retardation			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Investigations			
Weight Decreased			
subjects affected / exposed	15 / 71 (21.13%)	4 / 27 (14.81%)	20 / 115 (17.39%)
occurrences (all)	15	4	20
Alanine Aminotransferase Increased			
subjects affected / exposed	2 / 71 (2.82%)	2 / 27 (7.41%)	5 / 115 (4.35%)
occurrences (all)	2	2	5
Aspartate Aminotransferase Increased			

subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	5 / 115 (4.35%)
occurrences (all)	2	0	5
International Normalised Ratio Increased			
subjects affected / exposed	1 / 71 (1.41%)	2 / 27 (7.41%)	4 / 115 (3.48%)
occurrences (all)	1	2	4
Weight Increased			
subjects affected / exposed	2 / 71 (2.82%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	2	1	0
Blood Lactate Dehydrogenase Increased			
subjects affected / exposed	5 / 71 (7.04%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	5	0	1
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	2	0	2
C-Reactive Protein Increased			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	2 / 115 (1.74%)
occurrences (all)	1	1	2
Blood Uric Acid Increased			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	2	0	2
Electrocardiogram Qt Prolonged			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Activated Partial Thromboplastin Time Prolonged			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Blood Creatine Phosphokinase Increased			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Blood Thyroid Stimulating Hormone Increased			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
General Physical Condition Abnormal			

subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Blood Creatine Phosphokinase Decreased			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Blood Pressure Decreased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Blood Urea Increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Cardiac Murmur			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Ejection Fraction Decreased			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Electrocardiogram Change			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Hypophonesis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Oxygen Saturation Decreased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Transaminases Increased			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Alpha 1 Foetoprotein Increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Astrovirus Test Positive			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0

Bilirubin Urine			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Blast Cell Count Increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Bleeding Time Prolonged			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Blood Alkaline Phosphatase Decreased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Blood Lactic Acid Increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Blood Test Abnormal			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Body Temperature Increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Gamma-Glutamyltransferase Increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Glomerular Filtration Rate Decreased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Liver Function Test Increased			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Prothrombin Time Prolonged			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
White Blood Cell Count			

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
White Blood Cell Count Increased			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	5 / 71 (7.04%)	2 / 27 (7.41%)	5 / 115 (4.35%)
occurrences (all)	5	2	5
Fall			
subjects affected / exposed	6 / 71 (8.45%)	2 / 27 (7.41%)	9 / 115 (7.83%)
occurrences (all)	6	2	9
Infusion Related Reaction			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Laceration			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Procedural Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Skin Abrasion			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Transfusion Reaction			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Allergic Transfusion Reaction			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Animal Bite			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Head Injury			

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Joint Injury			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Overdose			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Periorbital Haematoma			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Post Procedural Contusion			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Post Procedural Haemorrhage			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Sunburn			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Tooth Fracture			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Wound			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	5 / 71 (7.04%)	1 / 27 (3.70%)	4 / 115 (3.48%)
occurrences (all)	5	1	4
Sinus Tachycardia			
subjects affected / exposed	4 / 71 (5.63%)	1 / 27 (3.70%)	2 / 115 (1.74%)
occurrences (all)	4	1	2
Atrial Fibrillation			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1

Bradycardia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Acute Left Ventricular Failure			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Angina Pectoris			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Arrhythmia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Bundle Branch Block Right			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Cardiac Failure			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Cardiac Flutter			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Extrasystoles			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Sinus Bradycardia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Supraventricular Tachycardia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Tachycardia Paroxysmal			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0

Nervous system disorders			
Dysgeusia			
subjects affected / exposed	7 / 71 (9.86%)	3 / 27 (11.11%)	12 / 115 (10.43%)
occurrences (all)	7	3	12
Headache			
subjects affected / exposed	5 / 71 (7.04%)	3 / 27 (11.11%)	3 / 115 (2.61%)
occurrences (all)	5	3	3
Syncope			
subjects affected / exposed	3 / 71 (4.23%)	1 / 27 (3.70%)	5 / 115 (4.35%)
occurrences (all)	3	1	5
Dizziness			
subjects affected / exposed	12 / 71 (16.90%)	2 / 27 (7.41%)	18 / 115 (15.65%)
occurrences (all)	12	2	18
Presyncope			
subjects affected / exposed	1 / 71 (1.41%)	3 / 27 (11.11%)	3 / 115 (2.61%)
occurrences (all)	1	3	3
Somnolence			
subjects affected / exposed	4 / 71 (5.63%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	4	0	2
Ageusia			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	2 / 115 (1.74%)
occurrences (all)	1	1	2
Balance Disorder			
subjects affected / exposed	2 / 71 (2.82%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	2	1	1
Memory Impairment			
subjects affected / exposed	3 / 71 (4.23%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	3	0	1
Ataxia			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	1	1	1
Lethargy			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Polyneuropathy			

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Tremor			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Aphasia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Cognitive Disorder			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Dysarthria			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Neuropathy Peripheral			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Paraesthesia			
subjects affected / exposed	0 / 71 (0.00%)	2 / 27 (7.41%)	0 / 115 (0.00%)
occurrences (all)	0	2	0
Speech Disorder			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	1	1	0
Aphonia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Cogwheel Rigidity			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Coordination Abnormal			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Drizzling			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Dysaesthesia			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Encephalopathy			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Haemorrhage Intracranial			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Hemianopia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Hemianopia Homonymous			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Hypersomnia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Hypoaesthesia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Hyposmia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Migraine			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Parosmia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Peripheral Sensory Neuropathy			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Sensory Loss			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Synaesthesia			

subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	29 / 71 (40.85%)	7 / 27 (25.93%)	38 / 115 (33.04%)
occurrences (all)	29	7	38
Anaemia			
subjects affected / exposed	20 / 71 (28.17%)	7 / 27 (25.93%)	29 / 115 (25.22%)
occurrences (all)	20	7	29
Neutropenia			
subjects affected / exposed	6 / 71 (8.45%)	5 / 27 (18.52%)	17 / 115 (14.78%)
occurrences (all)	6	5	17
Leukopenia			
subjects affected / exposed	2 / 71 (2.82%)	3 / 27 (11.11%)	10 / 115 (8.70%)
occurrences (all)	2	3	10
Febrile neutropenia			
subjects affected / exposed	9 / 71 (12.68%)	2 / 27 (7.41%)	7 / 115 (6.09%)
occurrences (all)	9	2	7
Leukocytosis			
subjects affected / exposed	6 / 71 (8.45%)	2 / 27 (7.41%)	6 / 115 (5.22%)
occurrences (all)	6	2	6
Lymphopenia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Pancytopenia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Coagulopathy			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	2 / 115 (1.74%)
occurrences (all)	0	1	2
Lymphadenopathy			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Increased Tendency To Bruise			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0

Polycythaemia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Splenomegaly			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Thrombocytosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Deafness			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	2	0	2
Ear Discomfort			
subjects affected / exposed	0 / 71 (0.00%)	2 / 27 (7.41%)	2 / 115 (1.74%)
occurrences (all)	0	2	2
Vertigo			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	0	0	3
Ear Pain			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	2	0	1
Tinnitus			
subjects affected / exposed	3 / 71 (4.23%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	3	0	0
Ear Congestion			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Eustachian Tube Dysfunction			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Excessive Cerumen Production			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Hypoacusis			

subjects affected / exposed occurrences (all)	1 / 71 (1.41%) 1	0 / 27 (0.00%) 0	0 / 115 (0.00%) 0
Eye disorders			
Vision blurred			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 71 (11.27%)	1 / 27 (3.70%)	9 / 115 (7.83%)
occurrences (all)	8	1	9
Visual Impairment			
subjects affected / exposed	4 / 71 (5.63%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	4	0	2
Cataract			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	3 / 115 (2.61%)
occurrences (all)	0	1	3
Dry Eye			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	1	1	1
Visual Acuity Reduced			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Conjunctival Haemorrhage			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Eye Pain			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Lacrimation Increased			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	1	1	1
Eye Haemorrhage			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Eyelid Oedema			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Ocular Hyperaemia			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Periorbital Oedema			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	1	1	0
Photopsia			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Retinal Haemorrhage			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Diplopia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Eye Inflammation			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Eye Swelling			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Eyelid Ptosis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Vitreous Floaters			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Vitreous Haemorrhage			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Nausea			
alternative assessment type: Systematic			
subjects affected / exposed	41 / 71 (57.75%)	16 / 27 (59.26%)	68 / 115 (59.13%)
occurrences (all)	41	16	68
Diarrhoea			
alternative assessment type: Systematic			

subjects affected / exposed	17 / 71 (23.94%)	13 / 27 (48.15%)	41 / 115 (35.65%)
occurrences (all)	17	13	41
Constipation			
alternative assessment type: Systematic			
subjects affected / exposed	20 / 71 (28.17%)	8 / 27 (29.63%)	25 / 115 (21.74%)
occurrences (all)	20	8	25
Vomiting			
alternative assessment type: Systematic			
subjects affected / exposed	19 / 71 (26.76%)	10 / 27 (37.04%)	30 / 115 (26.09%)
occurrences (all)	19	10	30
Stomatitis			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 71 (11.27%)	0 / 27 (0.00%)	8 / 115 (6.96%)
occurrences (all)	8	0	8
Abdominal pain			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	12 / 115 (10.43%)
occurrences (all)	1	0	12
Abdominal Pain Upper			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	6 / 115 (5.22%)
occurrences (all)	1	1	6
Dyspepsia			
subjects affected / exposed	3 / 71 (4.23%)	2 / 27 (7.41%)	3 / 115 (2.61%)
occurrences (all)	3	2	3
Gingival Bleeding			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	7 / 115 (6.09%)
occurrences (all)	0	0	7
Haemorrhoids			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	1	0	3
Aphthous Ulcer			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	1	1	1
Mouth Haemorrhage			

subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	4 / 115 (3.48%)
occurrences (all)	1	1	4
Abdominal Discomfort			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	0	1	1
Gingival Pain			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	1	0	3
Odynophagia			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	1	1	0
Toothache			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	2	0	3
Dry Mouth			
subjects affected / exposed	2 / 71 (2.82%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	2	1	1
Gastrooesophageal Reflux Disease			
subjects affected / exposed	3 / 71 (4.23%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	3	0	2
Dysphagia			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	2	0	1
Flatulence			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	0	0	3
Melaena			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Abdominal Pain Lower			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Anal Fissure			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Angina Bullosa Haemorrhagica			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Enterocolitis			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	0	1	1
Eructation			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Gastritis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Gastrointestinal Haemorrhage			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Mouth Ulceration			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Oral Disorder			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Oral Mucosa Haematoma			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Oral Mucosal Blistering			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Abdominal Tenderness			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Anal Incontinence			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Breath Odour			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Diverticulum			

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Faeces Soft			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Gingival Hypertrophy			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Glossitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Ileus			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Inguinal Hernia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Lip Blister			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Lip Dry			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Lip Oedema			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Lip Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Lip Swelling			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Lip Ulceration			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Mouth Swelling			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Oesophagitis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Oral Dysaesthesia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Palatal Disorder			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Perianal Erythema			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Proctalgia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Rectal Fissure			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Rectal Haemorrhage			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Retching			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Salivary Hypersecretion			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Tongue Haematoma			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Tongue Ulceration			

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Tooth Loss			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Trichoglossia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Oral Contusion			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Oral Pain			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	5 / 115 (4.35%)
occurrences (all)	2	0	5
Cholelithiasis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Hepatomegaly			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Jaundice			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Ocular Icterus			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Night sweats			
subjects affected / exposed	8 / 71 (11.27%)	3 / 27 (11.11%)	10 / 115 (8.70%)
occurrences (all)	8	3	10
Petechiae			

subjects affected / exposed	4 / 71 (5.63%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	4	0	3
Hyperhidrosis			
subjects affected / exposed	6 / 71 (8.45%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	6	0	3
Rash			
subjects affected / exposed	2 / 71 (2.82%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	2	1	1
Rash Maculo-Papular			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	1	0	3
Ecchymosis			
subjects affected / exposed	3 / 71 (4.23%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	3	0	1
Pruritus			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	2 / 115 (1.74%)
occurrences (all)	1	1	2
Skin Lesion			
subjects affected / exposed	3 / 71 (4.23%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	3	0	1
Skin Ulcer			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	2 / 115 (1.74%)
occurrences (all)	1	1	2
Alopecia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Decubitus Ulcer			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Erythema			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Cold Sweat			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Dermatitis			

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Purpura			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Skin Mass			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Swelling Face			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Dermal Cyst			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Dermatitis Acneiform			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Dermatitis Bullous			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Dry Skin			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Facial Wasting			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Macule			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Miliaria			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Nail Disorder			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Photosensitivity Reaction			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Rash Erythematous			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Rash Pruritic			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Skin Discolouration			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Skin Hyperpigmentation			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Skin Induration			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Skin Maceration			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute Kidney Injury			
subjects affected / exposed	8 / 71 (11.27%)	2 / 27 (7.41%)	3 / 115 (2.61%)
occurrences (all)	8	2	3
Haematuria			
subjects affected / exposed	3 / 71 (4.23%)	3 / 27 (11.11%)	1 / 115 (0.87%)
occurrences (all)	3	3	1
Pollakiuria			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	2	0	3
Proteinuria			
subjects affected / exposed	3 / 71 (4.23%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	3	1	1

Dysuria			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	2 / 115 (1.74%)
occurrences (all)	1	1	2
Renal Failure			
subjects affected / exposed	2 / 71 (2.82%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	2	1	1
Urinary Incontinence			
subjects affected / exposed	2 / 71 (2.82%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	2	1	1
Urinary Retention			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	2 / 115 (1.74%)
occurrences (all)	0	1	2
Bladder Dilatation			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Chronic Kidney Disease			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Micturition Urgency			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Bladder Pain			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Chromaturia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Incontinence			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Nocturia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Polyuria			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1

Urethral Caruncle subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Urethral Haemorrhage subjects affected / exposed occurrences (all)	1 / 71 (1.41%) 1	0 / 27 (0.00%) 0	0 / 115 (0.00%) 0
Urge Incontinence subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Urinary Tract Obstruction subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	0 / 115 (0.00%) 0
Urinary Tract Pain subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	1 / 27 (3.70%) 1	0 / 115 (0.00%) 0
Endocrine disorders			
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	1 / 27 (3.70%) 1	4 / 115 (3.48%) 4
Cushingoid subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	0 / 27 (0.00%) 0	1 / 115 (0.87%) 1
Hyperthyroidism subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	1 / 27 (3.70%) 1	0 / 115 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	5 / 71 (7.04%) 5	0 / 27 (0.00%) 0	6 / 115 (5.22%) 6
Back Pain subjects affected / exposed occurrences (all)	0 / 71 (0.00%) 0	1 / 27 (3.70%) 1	6 / 115 (5.22%) 6
Muscular Weakness subjects affected / exposed occurrences (all)	5 / 71 (7.04%) 5	0 / 27 (0.00%) 0	4 / 115 (3.48%) 4
Pain In Extremity			

subjects affected / exposed	4 / 71 (5.63%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	4	0	3
Muscle Spasms			
subjects affected / exposed	1 / 71 (1.41%)	2 / 27 (7.41%)	2 / 115 (1.74%)
occurrences (all)	1	2	2
Bone Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	5 / 115 (4.35%)
occurrences (all)	0	0	5
Musculoskeletal Pain			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Myalgia			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	2	0	1
Neck Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Arthritis			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	0	1	1
Flank Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Hypercreatinaemia			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Joint Swelling			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Musculoskeletal Chest Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Pain In Jaw			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Bursitis			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Groin Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Ligament Pain			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Limb Discomfort			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Limb Mass			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Muscle Mass			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Muscle Tightness			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Muscle Twitching			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Osteitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Osteoarthritis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Spinal Osteoarthritis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Torticollis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			

Urinary Tract Infection			
subjects affected / exposed	6 / 71 (8.45%)	2 / 27 (7.41%)	9 / 115 (7.83%)
occurrences (all)	6	2	9
Oral Herpes			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	2	0	3
Nasopharyngitis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	5 / 115 (4.35%)
occurrences (all)	1	0	5
Oral Candidiasis			
subjects affected / exposed	4 / 71 (5.63%)	0 / 27 (0.00%)	4 / 115 (3.48%)
occurrences (all)	4	0	4
Pneumonia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	4 / 115 (3.48%)
occurrences (all)	1	0	4
Cellulitis			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	2	0	2
Lung Infection			
subjects affected / exposed	2 / 71 (2.82%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	2	1	1
Sinusitis			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	2 / 115 (1.74%)
occurrences (all)	0	1	2
Upper Respiratory Tract Infection			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Device Related Infection			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Periodontitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Pneumonia Fungal			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0

Sepsis			
subjects affected / exposed	1 / 71 (1.41%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	1	1	1
Candida Infection			
subjects affected / exposed	3 / 71 (4.23%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	3	0	0
Folliculitis			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	2 / 115 (1.74%)
occurrences (all)	0	1	2
Oesophageal Candidiasis			
subjects affected / exposed	0 / 71 (0.00%)	2 / 27 (7.41%)	0 / 115 (0.00%)
occurrences (all)	0	2	0
Skin Infection			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Staphylococcal Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Clostridium Difficile Colitis			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	0	1	1
Clostridium Difficile Infection			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Conjunctivitis			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	0	1	1
Ear Infection			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Fungal Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	0	0	2
Herpes Dermatitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1

Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Lip Infection			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	0	1	1
Nasal Herpes			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	1	0	1
Pharyngitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Pseudomonas Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Rash Pustular			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Rhinovirus Infection			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Soft Tissue Infection			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Abscess Limb			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Acute Sinusitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Anal Abscess			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Aspergillus Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1

Asymptomatic Bacteriuria			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Bacterial Infection			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Bacteriuria			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Bronchitis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Catheter Site Cellulitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Clostridium Colitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Dermo-Hypodermatitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Diverticulitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Emphyema			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Encephalitis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Enterobiasis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Enterococcal Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1

Furuncle			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Genital Herpes			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Gingivitis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Groin Infection			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Herpes Simplex			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Herpes Zoster			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Infected Dermal Cyst			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Influenza			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Lower Respiratory Tract Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Lymph Gland Infection			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Meningitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Metapneumovirus Infection			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0

Mucosal Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Oesophageal Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Ophthalmic Herpes Simplex			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Oral Fungal Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Oral Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Osteomyelitis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Parotitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Pneumonia Klebsiella			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Proteus Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Pseudomembranous Colitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Respiratory Tract Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1

Septic Shock			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Sialoadenitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Staphylococcal Bacteraemia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Stenotrophomonas Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Tonsillitis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Tonsillitis Bacterial			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Tooth Abscess			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Tooth Infection			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0
Varicella Zoster Virus Infection			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Hallucination			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	0	0	3
Personality Change			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Facial Bones Fracture			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	0	0	0

Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	26 / 71 (36.62%)	6 / 27 (22.22%)	25 / 115 (21.74%)
occurrences (all)	26	6	25
Hypokalaemia			
subjects affected / exposed	10 / 71 (14.08%)	1 / 27 (3.70%)	9 / 115 (7.83%)
occurrences (all)	10	1	9
Hypocalcaemia			
subjects affected / exposed	5 / 71 (7.04%)	2 / 27 (7.41%)	11 / 115 (9.57%)
occurrences (all)	5	2	11
Hypercreatininaemia			
subjects affected / exposed	5 / 71 (7.04%)	0 / 27 (0.00%)	13 / 115 (11.30%)
occurrences (all)	5	0	13
Hypomagnesaemia			
subjects affected / exposed	7 / 71 (9.86%)	0 / 27 (0.00%)	9 / 115 (7.83%)
occurrences (all)	7	0	9
Hyperglycaemia			
subjects affected / exposed	6 / 71 (8.45%)	3 / 27 (11.11%)	7 / 115 (6.09%)
occurrences (all)	6	3	7
Hyperkalaemia			
subjects affected / exposed	8 / 71 (11.27%)	2 / 27 (7.41%)	9 / 115 (7.83%)
occurrences (all)	8	2	9
Dehydration			
subjects affected / exposed	8 / 71 (11.27%)	0 / 27 (0.00%)	6 / 115 (5.22%)
occurrences (all)	8	0	6
Hypophosphataemia			
subjects affected / exposed	9 / 71 (12.68%)	1 / 27 (3.70%)	5 / 115 (4.35%)
occurrences (all)	9	1	5
Hyperuricaemia			
subjects affected / exposed	5 / 71 (7.04%)	1 / 27 (3.70%)	2 / 115 (1.74%)
occurrences (all)	5	1	2
Hypoalbuminaemia			
subjects affected / exposed	4 / 71 (5.63%)	1 / 27 (3.70%)	1 / 115 (0.87%)
occurrences (all)	4	1	1
Hypercalcaemia			

subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	4 / 115 (3.48%)
occurrences (all)	0	0	4
Hypermagnesaemia			
subjects affected / exposed	3 / 71 (4.23%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	3	0	1
Cachexia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	3 / 115 (2.61%)
occurrences (all)	0	1	3
Hyperlipasaemia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	1	0	3
Hyperphosphataemia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	3 / 115 (2.61%)
occurrences (all)	0	0	3
Hypoglycaemia			
subjects affected / exposed	3 / 71 (4.23%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	3	0	1
Fluid Retention			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Hyperamylasaemia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	2 / 115 (1.74%)
occurrences (all)	1	0	2
Fluid Overload			
subjects affected / exposed	2 / 71 (2.82%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	2	0	0
Tumour Lysis Syndrome			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Type 2 Diabetes Mellitus			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Diabetes Mellitus			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Failure To Thrive			

subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Gout			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Hyperglycaemic Hyperosmolar Nonketotic Syndrome			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Hyperhomocysteinaemia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Hypernatraemia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1
Hypouricaemia			
subjects affected / exposed	0 / 71 (0.00%)	1 / 27 (3.70%)	0 / 115 (0.00%)
occurrences (all)	0	1	0
Metabolic Acidosis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 27 (0.00%)	0 / 115 (0.00%)
occurrences (all)	1	0	0
Polydipsia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 27 (0.00%)	1 / 115 (0.87%)
occurrences (all)	0	0	1

Non-serious adverse events	Physician's Choice 1 (PV <5)	Physician's Choice 2 (PV ≥5)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	37 / 39 (94.87%)	40 / 45 (88.89%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute Myeloid Leukaemia			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Basal Cell Carcinoma			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Chloroma			

subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Leukaemic Infiltration			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Uterine Leiomyoma			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Vascular disorders			
Hypotension			
subjects affected / exposed	4 / 39 (10.26%)	1 / 45 (2.22%)	
occurrences (all)	4	1	
Haematoma			
subjects affected / exposed	7 / 39 (17.95%)	1 / 45 (2.22%)	
occurrences (all)	7	1	
Hypertension			
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Pallor			
subjects affected / exposed	2 / 39 (5.13%)	1 / 45 (2.22%)	
occurrences (all)	2	1	
Haemorrhage			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Phlebitis			
subjects affected / exposed	3 / 39 (7.69%)	0 / 45 (0.00%)	
occurrences (all)	3	0	
Thrombophlebitis			
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Orthostatic Hypotension			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Deep Vein Thrombosis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	

Flushing			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Circulatory Collapse			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Embolism			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Hot Flush			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Intermittent Claudication			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Lymphoedema			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Poor Peripheral Circulation			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Thrombophlebitis Superficial			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Venous Thrombosis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	15 / 39 (38.46%)	13 / 45 (28.89%)	
occurrences (all)	15	13	
Pyrexia			
alternative assessment type: Systematic			
subjects affected / exposed	13 / 39 (33.33%)	13 / 45 (28.89%)	
occurrences (all)	13	13	
Oedema peripheral			

alternative assessment type: Systematic			
subjects affected / exposed	10 / 39 (25.64%)	5 / 45 (11.11%)	
occurrences (all)	10	5	
Asthenia			
alternative assessment type: Systematic			
subjects affected / exposed	5 / 39 (12.82%)	5 / 45 (11.11%)	
occurrences (all)	5	5	
Malaise			
subjects affected / exposed	3 / 39 (7.69%)	1 / 45 (2.22%)	
occurrences (all)	3	1	
Oedema			
subjects affected / exposed	4 / 39 (10.26%)	2 / 45 (4.44%)	
occurrences (all)	4	2	
Chills			
subjects affected / exposed	3 / 39 (7.69%)	1 / 45 (2.22%)	
occurrences (all)	3	1	
Mucosal Inflammation			
subjects affected / exposed	4 / 39 (10.26%)	3 / 45 (6.67%)	
occurrences (all)	4	3	
Pain			
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Gait Disturbance			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
General Physical Health Deterioration			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Injection Site Bruising			
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Non-Cardiac Chest Pain			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Ulcer			

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Catheter Site Haemorrhage			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Face Oedema			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Generalised Oedema			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Secretion Discharge			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Catheter Site Haematoma			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Chest Pain			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Drug Intolerance			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Extravasation			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Feeling Cold			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Granuloma			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Hernia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Impaired Healing			

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Infusion Site Haemorrhage			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Injection Site Discolouration			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Injection Site Pain			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Mucosal Dryness			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Nodule			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Peripheral Swelling			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Swelling			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Decreased appetite			
subjects affected / exposed	9 / 39 (23.08%)	7 / 45 (15.56%)	
occurrences (all)	9	7	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Reproductive system and breast disorders			
Breast Pain			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Breast Swelling			

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Gynaecomastia			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Nipple Pain			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Oedema Genital			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Ovarian Cyst			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Testicular Oedema			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Vaginal Haemorrhage			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	8 / 39 (20.51%)	10 / 45 (22.22%)	
occurrences (all)	8	10	
Epistaxis			
subjects affected / exposed	7 / 39 (17.95%)	7 / 45 (15.56%)	
occurrences (all)	7	7	
Cough			
subjects affected / exposed	5 / 39 (12.82%)	8 / 45 (17.78%)	
occurrences (all)	5	8	
Oropharyngeal Pain			
subjects affected / exposed	2 / 39 (5.13%)	3 / 45 (6.67%)	
occurrences (all)	2	3	
Productive Cough			

subjects affected / exposed	3 / 39 (7.69%)	1 / 45 (2.22%)
occurrences (all)	3	1
Haemoptysis		
subjects affected / exposed	1 / 39 (2.56%)	3 / 45 (6.67%)
occurrences (all)	1	3
Dyspnoea Exertional		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
Nasal Congestion		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Pleural Effusion		
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)
occurrences (all)	2	0
Hypoxia		
subjects affected / exposed	1 / 39 (2.56%)	2 / 45 (4.44%)
occurrences (all)	1	2
Rhinorrhoea		
subjects affected / exposed	0 / 39 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	2
Wheezing		
subjects affected / exposed	1 / 39 (2.56%)	2 / 45 (4.44%)
occurrences (all)	1	2
Atelectasis		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Hiccups		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Pleuritic Pain		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
Respiratory Failure		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Pulmonary Oedema		

subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Sinus Congestion		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Sinus Pain		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Upper-Airway Cough Syndrome		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
Chronic Obstructive Pulmonary Disease		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Dysphonia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Laryngeal Pain		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Lung Consolidation		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Lung Infiltration		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Nasal Dryness		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Nasal Inflammation		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Paranasal Sinus Discomfort		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0

Pharyngeal Inflammation			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Pneumonitis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Pulmonary Mass			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Rales			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Respiratory Tract Congestion			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Rhinitis Allergic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Rhonchi			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Sinus Disorder			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Tachypnoea			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Tonsillar Erythema			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Tonsillar Hypertrophy			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Psychiatric disorders			
Insomnia			

subjects affected / exposed	4 / 39 (10.26%)	3 / 45 (6.67%)
occurrences (all)	4	3
Confusional State		
subjects affected / exposed	2 / 39 (5.13%)	3 / 45 (6.67%)
occurrences (all)	2	3
Anxiety		
subjects affected / exposed	2 / 39 (5.13%)	1 / 45 (2.22%)
occurrences (all)	2	1
Depression		
subjects affected / exposed	3 / 39 (7.69%)	1 / 45 (2.22%)
occurrences (all)	3	1
Agitation		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Restlessness		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Abnormal Dreams		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Bulimia Nervosa		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Delirium		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Disorientation		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Flat Affect		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Hallucination, Visual		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Irritability		

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Listless			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Mental Disorder			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Mental Status Changes			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Nervousness			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Psychomotor Retardation			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Investigations			
Weight Decreased			
subjects affected / exposed	3 / 39 (7.69%)	3 / 45 (6.67%)	
occurrences (all)	3	3	
Alanine Aminotransferase Increased			
subjects affected / exposed	2 / 39 (5.13%)	1 / 45 (2.22%)	
occurrences (all)	2	1	
Aspartate Aminotransferase Increased			
subjects affected / exposed	2 / 39 (5.13%)	1 / 45 (2.22%)	
occurrences (all)	2	1	
International Normalised Ratio Increased			
subjects affected / exposed	3 / 39 (7.69%)	0 / 45 (0.00%)	
occurrences (all)	3	0	
Weight Increased			
subjects affected / exposed	6 / 39 (15.38%)	1 / 45 (2.22%)	
occurrences (all)	6	1	
Blood Lactate Dehydrogenase Increased			

subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Blood Alkaline Phosphatase Increased		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
C-Reactive Protein Increased		
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)
occurrences (all)	2	0
Blood Uric Acid Increased		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Electrocardiogram Qt Prolonged		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
Activated Partial Thromboplastin Time Prolonged		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Blood Creatine Phosphokinase Increased		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Blood Thyroid Stimulating Hormone Increased		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
General Physical Condition Abnormal		
subjects affected / exposed	0 / 39 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	2
Blood Creatine Phosphokinase Decreased		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Blood Pressure Decreased		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Blood Urea Increased		

subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Cardiac Murmur		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Ejection Fraction Decreased		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Electrocardiogram Change		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Hypophonesis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Oxygen Saturation Decreased		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Transaminases Increased		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Alpha 1 Foetoprotein Increased		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Astrovirus Test Positive		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Bilirubin Urine		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Blast Cell Count Increased		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Bleeding Time Prolonged		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Blood Alkaline Phosphatase		

Decreased subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 45 (0.00%) 0	
Blood Lactic Acid Increased subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	1 / 45 (2.22%) 1	
Blood Test Abnormal subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 45 (0.00%) 0	
Body Temperature Increased subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	0 / 45 (0.00%) 0	
Gamma-Glutamyltransferase Increased subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	0 / 45 (0.00%) 0	
Glomerular Filtration Rate Decreased subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 45 (0.00%) 0	
Liver Function Test Increased subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 45 (0.00%) 0	
Prothrombin Time Prolonged subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 45 (0.00%) 0	
White Blood Cell Count subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 45 (0.00%) 0	
White Blood Cell Count Increased subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	1 / 45 (2.22%) 1	
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 3	1 / 45 (2.22%) 1	
Fall			

subjects affected / exposed	2 / 39 (5.13%)	2 / 45 (4.44%)
occurrences (all)	2	2
Infusion Related Reaction		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
Laceration		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Procedural Pain		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Skin Abrasion		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Transfusion Reaction		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Allergic Transfusion Reaction		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Animal Bite		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Head Injury		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Joint Injury		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Overdose		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Periorbital Haematoma		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Post Procedural Contusion		

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Post Procedural Haemorrhage			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Sunburn			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Tooth Fracture			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Wound			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 39 (0.00%)	2 / 45 (4.44%)	
occurrences (all)	0	2	
Sinus Tachycardia			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Atrial Fibrillation			
subjects affected / exposed	2 / 39 (5.13%)	1 / 45 (2.22%)	
occurrences (all)	2	1	
Bradycardia			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Acute Left Ventricular Failure			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Angina Pectoris			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Arrhythmia			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	

Bundle Branch Block Right			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Cardiac Failure			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Cardiac Flutter			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Extrasystoles			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Palpitations			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Sinus Bradycardia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Supraventricular Tachycardia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Tachycardia Paroxysmal			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
Dysgeusia			
subjects affected / exposed	3 / 39 (7.69%)	2 / 45 (4.44%)	
occurrences (all)	3	2	
Headache			
subjects affected / exposed	7 / 39 (17.95%)	6 / 45 (13.33%)	
occurrences (all)	7	6	
Syncope			
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)	
occurrences (all)	2	0	
Dizziness			

subjects affected / exposed	8 / 39 (20.51%)	2 / 45 (4.44%)
occurrences (all)	8	2
Presyncope		
subjects affected / exposed	0 / 39 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	2
Somnolence		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Ageusia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Balance Disorder		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Memory Impairment		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Ataxia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Lethargy		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Polyneuropathy		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Tremor		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Aphasia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Cognitive Disorder		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Dysarthria		

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Neuropathy Peripheral			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Paraesthesia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Speech Disorder			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Aphonia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Cogwheel Rigidity			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Coordination Abnormal			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Drooling			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Dysaesthesia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Encephalopathy			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Haemorrhage Intracranial			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Hemianopia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Hemianopia Homonymous			

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Hypersomnia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Hypoaesthesia			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Hyposmia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Migraine			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Parosmia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Peripheral Sensory Neuropathy			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Sensory Loss			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Synaesthesia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	18 / 39 (46.15%)	11 / 45 (24.44%)	
occurrences (all)	18	11	
Anaemia			
subjects affected / exposed	17 / 39 (43.59%)	10 / 45 (22.22%)	
occurrences (all)	17	10	
Neutropenia			
subjects affected / exposed	10 / 39 (25.64%)	9 / 45 (20.00%)	
occurrences (all)	10	9	

Leukopenia			
subjects affected / exposed	5 / 39 (12.82%)	4 / 45 (8.89%)	
occurrences (all)	5	4	
Febrile neutropenia			
subjects affected / exposed	3 / 39 (7.69%)	2 / 45 (4.44%)	
occurrences (all)	3	2	
Leukocytosis			
subjects affected / exposed	4 / 39 (10.26%)	0 / 45 (0.00%)	
occurrences (all)	4	0	
Lymphopenia			
subjects affected / exposed	2 / 39 (5.13%)	1 / 45 (2.22%)	
occurrences (all)	2	1	
Pancytopenia			
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)	
occurrences (all)	2	0	
Coagulopathy			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Lymphadenopathy			
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Increased Tendency To Bruise			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	0	
Polycythaemia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Splenomegaly			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Thrombocytosis			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			
Deafness			

subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Ear Discomfort			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Vertigo			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Ear Pain			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Tinnitus			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Ear Congestion			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Eustachian Tube Dysfunction			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Excessive Cerumen Production			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Hypoacusis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Eye disorders			
Vision blurred			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Visual Impairment			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Cataract			

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Dry Eye		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Visual Acuity Reduced		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Conjunctival Haemorrhage		
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)
occurrences (all)	2	0
Eye Pain		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Lacrimation Increased		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Eye Haemorrhage		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Eyelid Oedema		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Ocular Hyperaemia		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Periorbital Oedema		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Photopsia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Retinal Haemorrhage		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Diplopia		

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Eye Inflammation			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Eye Swelling			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Eyelid Ptosis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Vitreous Floaters			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Vitreous Haemorrhage			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			
Nausea			
alternative assessment type: Systematic			
subjects affected / exposed	13 / 39 (33.33%)	8 / 45 (17.78%)	
occurrences (all)	13	8	
Diarrhoea			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 39 (20.51%)	6 / 45 (13.33%)	
occurrences (all)	8	6	
Constipation			
alternative assessment type: Systematic			
subjects affected / exposed	16 / 39 (41.03%)	15 / 45 (33.33%)	
occurrences (all)	16	15	
Vomiting			
alternative assessment type: Systematic			
subjects affected / exposed	7 / 39 (17.95%)	6 / 45 (13.33%)	
occurrences (all)	7	6	
Stomatitis			

alternative assessment type: Systematic			
subjects affected / exposed	3 / 39 (7.69%)	3 / 45 (6.67%)	
occurrences (all)	3	3	
Abdominal pain			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 39 (5.13%)	6 / 45 (13.33%)	
occurrences (all)	2	6	
Abdominal Pain Upper			
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Dyspepsia			
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Gingival Bleeding			
subjects affected / exposed	1 / 39 (2.56%)	2 / 45 (4.44%)	
occurrences (all)	1	2	
Haemorrhoids			
subjects affected / exposed	2 / 39 (5.13%)	3 / 45 (6.67%)	
occurrences (all)	2	3	
Aphthous Ulcer			
subjects affected / exposed	2 / 39 (5.13%)	2 / 45 (4.44%)	
occurrences (all)	2	2	
Mouth Haemorrhage			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Abdominal Discomfort			
subjects affected / exposed	2 / 39 (5.13%)	2 / 45 (4.44%)	
occurrences (all)	2	2	
Gingival Pain			
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)	
occurrences (all)	2	0	
Odynophagia			
subjects affected / exposed	2 / 39 (5.13%)	2 / 45 (4.44%)	
occurrences (all)	2	2	
Toothache			

subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Dry Mouth		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Gastrooesophageal Reflux Disease		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Dysphagia		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Flatulence		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Melaena		
subjects affected / exposed	1 / 39 (2.56%)	2 / 45 (4.44%)
occurrences (all)	1	2
Abdominal Pain Lower		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Anal Fissure		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Angina Bullosa Haemorrhagica		
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)
occurrences (all)	2	0
Enterocolitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Eructation		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Gastritis		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Gastrointestinal Haemorrhage		

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Mouth Ulceration		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Oral Disorder		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Oral Mucosa Haematoma		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Oral Mucosal Blistering		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Abdominal Tenderness		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Anal Incontinence		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Breath Odour		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Diverticulum		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Faeces Soft		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Gastrointestinal Pain		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Gingival Hypertrophy		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Glossitis		

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Ileus		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Inguinal Hernia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Lip Blister		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Lip Dry		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Lip Oedema		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Lip Pain		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Lip Swelling		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Lip Ulceration		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Mouth Swelling		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Oesophagitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Oral Dysaesthesia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Palatal Disorder		

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Perianal Erythema			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Proctalgia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Rectal Fissure			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Rectal Haemorrhage			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Retching			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Salivary Hypersecretion			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Tongue Haematoma			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Tongue Ulceration			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Tooth Loss			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Trichoglossia			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Oral Contusion			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Oral Pain			

subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 45 (0.00%) 0	
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Cholelithiasis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Hepatomegaly			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Jaundice			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Ocular Icterus			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Skin and subcutaneous tissue disorders			
Night sweats			
subjects affected / exposed	1 / 39 (2.56%)	4 / 45 (8.89%)	
occurrences (all)	1	4	
Petechiae			
subjects affected / exposed	7 / 39 (17.95%)	6 / 45 (13.33%)	
occurrences (all)	7	6	
Hyperhidrosis			
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Rash			
subjects affected / exposed	4 / 39 (10.26%)	2 / 45 (4.44%)	
occurrences (all)	4	2	
Rash Maculo-Papular			
subjects affected / exposed	2 / 39 (5.13%)	2 / 45 (4.44%)	
occurrences (all)	2	2	
Ecchymosis			

subjects affected / exposed	1 / 39 (2.56%)	2 / 45 (4.44%)
occurrences (all)	1	2
Pruritus		
subjects affected / exposed	2 / 39 (5.13%)	1 / 45 (2.22%)
occurrences (all)	2	1
Skin Lesion		
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)
occurrences (all)	2	0
Skin Ulcer		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Alopecia		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Decubitus Ulcer		
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)
occurrences (all)	2	0
Erythema		
subjects affected / exposed	0 / 39 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	2
Cold Sweat		
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)
occurrences (all)	2	0
Dermatitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Purpura		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Skin Mass		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Swelling Face		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Dermal Cyst		

subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Dermatitis Acneiform		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Dermatitis Bullous		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Dry Skin		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Facial Wasting		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Macule		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Miliaria		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Nail Disorder		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Photosensitivity Reaction		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Rash Erythematous		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Rash Pruritic		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Skin Discolouration		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Skin Hyperpigmentation		

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Skin Induration			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Skin Maceration			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Urticaria			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Acute Kidney Injury			
subjects affected / exposed	2 / 39 (5.13%)	3 / 45 (6.67%)	
occurrences (all)	2	3	
Haematuria			
subjects affected / exposed	2 / 39 (5.13%)	3 / 45 (6.67%)	
occurrences (all)	2	3	
Pollakiuria			
subjects affected / exposed	1 / 39 (2.56%)	2 / 45 (4.44%)	
occurrences (all)	1	2	
Proteinuria			
subjects affected / exposed	2 / 39 (5.13%)	1 / 45 (2.22%)	
occurrences (all)	2	1	
Dysuria			
subjects affected / exposed	0 / 39 (0.00%)	2 / 45 (4.44%)	
occurrences (all)	0	2	
Renal Failure			
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)	
occurrences (all)	1	1	
Urinary Incontinence			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Urinary Retention			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	

Bladder Dilatation		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Chronic Kidney Disease		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Micturition Urgency		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Bladder Pain		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Chromaturia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Incontinence		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Nocturia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Polyuria		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Urethral Caruncle		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Urethral Haemorrhage		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Urge Incontinence		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Urinary Tract Obstruction		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1

Urinary Tract Pain subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 45 (0.00%) 0	
Endocrine disorders			
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	0 / 45 (0.00%) 0	
Cushingoid subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 45 (0.00%) 0	
Hyperthyroidism subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 45 (0.00%) 0	
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	5 / 39 (12.82%) 5	1 / 45 (2.22%) 1	
Back Pain subjects affected / exposed occurrences (all)	5 / 39 (12.82%) 5	5 / 45 (11.11%) 5	
Muscular Weakness subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 3	0 / 45 (0.00%) 0	
Pain In Extremity subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	2 / 45 (4.44%) 2	
Muscle Spasms subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	3 / 45 (6.67%) 3	
Bone Pain subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	0 / 45 (0.00%) 0	
Musculoskeletal Pain subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 45 (0.00%) 0	
Myalgia			

subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)
occurrences (all)	2	0
Neck Pain		
subjects affected / exposed	1 / 39 (2.56%)	2 / 45 (4.44%)
occurrences (all)	1	2
Arthritis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Flank Pain		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
Hypercreatinaemia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Joint Swelling		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Musculoskeletal Chest Pain		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
Pain In Jaw		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Bursitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Groin Pain		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Ligament Pain		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Limb Discomfort		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Limb Mass		

subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Muscle Mass			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Muscle Tightness			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Muscle Twitching			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Osteitis			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Osteoarthritis			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Spinal Osteoarthritis			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Torticollis			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Infections and infestations			
Urinary Tract Infection			
subjects affected / exposed	5 / 39 (12.82%)	2 / 45 (4.44%)	
occurrences (all)	5	2	
Oral Herpes			
subjects affected / exposed	4 / 39 (10.26%)	4 / 45 (8.89%)	
occurrences (all)	4	4	
Nasopharyngitis			
subjects affected / exposed	1 / 39 (2.56%)	3 / 45 (6.67%)	
occurrences (all)	1	3	
Oral Candidiasis			
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)	
occurrences (all)	1	1	

Pneumonia		
subjects affected / exposed	3 / 39 (7.69%)	1 / 45 (2.22%)
occurrences (all)	3	1
Cellulitis		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
Lung Infection		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Sinusitis		
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)
occurrences (all)	2	0
Upper Respiratory Tract Infection		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
Device Related Infection		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Periodontitis		
subjects affected / exposed	0 / 39 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	2
Pneumonia Fungal		
subjects affected / exposed	0 / 39 (0.00%)	3 / 45 (6.67%)
occurrences (all)	0	3
Sepsis		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Candida Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Folliculitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Oesophageal Candidiasis		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0

Skin Infection		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Staphylococcal Infection		
subjects affected / exposed	0 / 39 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	2
Clostridium Difficile Colitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Clostridium Difficile Infection		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Conjunctivitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Ear Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Fungal Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Herpes Dermatitis		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Infection		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
Lip Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Nasal Herpes		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Pharyngitis		
subjects affected / exposed	2 / 39 (5.13%)	0 / 45 (0.00%)
occurrences (all)	2	0

Pseudomonas Infection		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Rash Pustular		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Rhinovirus Infection		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Soft Tissue Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Abscess Limb		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Acute Sinusitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Anal Abscess		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Aspergillus Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Asymptomatic Bacteriuria		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Bacterial Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Bacteriuria		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Bronchitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0

Catheter Site Cellulitis		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Clostridium Colitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Dermo-Hypodermatitis		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Diverticulitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Empyema		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Encephalitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Enterobiasis		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Enterococcal Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Furuncle		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Genital Herpes		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Gingivitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Groin Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0

Herpes Simplex		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Herpes Zoster		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Infected Dermal Cyst		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Influenza		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Lower Respiratory Tract Infection		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Lymph Gland Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Meningitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Metapneumovirus Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Mucosal Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Oesophageal Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Ophthalmic Herpes Simplex		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Oral Fungal Infection		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0

Oral Infection		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Osteomyelitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Parotitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Pneumonia Klebsiella		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Proteus Infection		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Pseudomembranous Colitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Respiratory Tract Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Rhinitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Septic Shock		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Sialoadenitis		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Staphylococcal Bacteraemia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Stenotrophomonas Infection		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0

Tonsillitis			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Tonsillitis Bacterial			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Tooth Abscess			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Tooth Infection			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Varicella Zoster Virus Infection			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Hallucination			
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)	
occurrences (all)	0	1	
Personality Change			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Facial Bones Fracture			
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	3 / 39 (7.69%)	1 / 45 (2.22%)	
occurrences (all)	3	1	
Hypokalaemia			
subjects affected / exposed	5 / 39 (12.82%)	6 / 45 (13.33%)	
occurrences (all)	5	6	
Hypocalcaemia			
subjects affected / exposed	2 / 39 (5.13%)	4 / 45 (8.89%)	
occurrences (all)	2	4	
Hypercreatininaemia			

subjects affected / exposed	2 / 39 (5.13%)	1 / 45 (2.22%)
occurrences (all)	2	1
Hypomagnesaemia		
subjects affected / exposed	2 / 39 (5.13%)	3 / 45 (6.67%)
occurrences (all)	2	3
Hyperglycaemia		
subjects affected / exposed	1 / 39 (2.56%)	3 / 45 (6.67%)
occurrences (all)	1	3
Hyperkalaemia		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Dehydration		
subjects affected / exposed	3 / 39 (7.69%)	2 / 45 (4.44%)
occurrences (all)	3	2
Hypophosphataemia		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Hyperuricaemia		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
Hypoalbuminaemia		
subjects affected / exposed	2 / 39 (5.13%)	2 / 45 (4.44%)
occurrences (all)	2	2
Hypercalcaemia		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Hypermagnesaemia		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Cachexia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Hyperlipasaemia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Hyperphosphataemia		

subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Hypoglycaemia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Fluid Retention		
subjects affected / exposed	1 / 39 (2.56%)	1 / 45 (2.22%)
occurrences (all)	1	1
Hyperamylasaemia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Fluid Overload		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Tumour Lysis Syndrome		
subjects affected / exposed	0 / 39 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	1
Type 2 Diabetes Mellitus		
subjects affected / exposed	1 / 39 (2.56%)	0 / 45 (0.00%)
occurrences (all)	1	0
Diabetes Mellitus		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Failure To Thrive		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Gout		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Hyperglycaemic Hyperosmolar Nonketotic Syndrome		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0
Hyperhomocysteinaemia		
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0

Hypernatraemia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Hypouricaemia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Metabolic Acidosis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	
Polydipsia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 45 (0.00%)	
occurrences (all)	0	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
03 July 2014	Revise the treatment goal for hypertension to be lower than Blood pressure = 150/100 mmHg, the original protocol limit, to reduce the risk of CNS bleeding given that thrombocytopenia was expected in subjects with this protocol regimen. The recommendation for treatment of hypertension was removed thereby allowing study sites to use their standard protocols.
25 November 2014	<ul style="list-style-type: none">• Address feedback from study Investigators regarding use of hydroxyurea and timing of dosing days and screening bone marrow aspirate.• Remove the restriction on acetaminophen except on days of selinexor dosing (≤ 1 g total daily dose of acetaminophen) and to add restrictions for products that may alter selinexor metabolism.• Update the supportive care guidance and selinexor dose adjustment information, as well as study procedures including ophthalmological exam.• Standardize reporting requirements for cerebellar toxicities (expanded reporting beyond FDA and the MHRA as in Version 2.1).
24 April 2015	<ul style="list-style-type: none">• Increase the assumed dropout rate to $\sim 20\%$ to align with the actual rate at study sites and increase the sample size to 170 subject to maintain power with the increased dropout rate.• Expand exclusion criteria to exclude subject with concurrent active malignancies that were not being treated.• Add EQ-5D-5L QoL questionnaire.• Add 20 mg tablets in blister packs as an option for selinexor drug product.• Remove specific recommendation for the use of dexamethasone as a supportive care agent.
04 August 2015	<ul style="list-style-type: none">• Address the unexpected increase in the number of infection-related AEs in subjects randomised to selinexor as compared to subjects randomised to the PC arm.• Reduce the selinexor dose from ~ 55 mg/square-metre (~ 80 to 100 mg) to a fixed dose of 60 mg (~ 35 mg/square-metre) to reduce selinexor-related adverse events, especially suspected sepsis cases as well as and pneumonia/lung infections in this highly compromised subjects population.• Revise the inclusion criteria to require at least 2 prior lines of AML therapy, including (1) at least 1 regimen including Ara-C and (2) at least 1 regimen including an adequate trial of an HMA in order to insure that subjects entering the study had been offered an adequate trial of agents currently used to treat AML in subjects ineligible for intensive chemotherapy with transplantation.• Add the exclusion criterion for subjects whose AML was classified as favorable according to the ELN disease risk assessment.• Revise the stratification to add a stratum for peripheral leukemic blast counts $\geq 10,000/\text{mCL}$ versus $< 10,000/\text{mCL}$ and to reduce the duration of the first CR on prior therapy from 1 year to 6 months.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported